目的:回顾性研究氮卓斯汀鼻喷雾剂联合贻贝黏蛋白治疗变应性鼻炎(AR)的疗效及CCL26和CC趋化因子受体3(CCR3)的作用。
方法:以我院2020年3月至2022年3月收治的80例AR患者为研究对象。通过回顾患者的治疗情况,根据不同的治疗策略将所有受试者分为两组。对照组(n=40)给予氮卓斯汀鼻喷雾剂,而研究组(n=40)采用贻贝粘蛋白和氮卓斯汀鼻喷雾剂联合治疗。临床疗效,临床症状,回顾性计算并比较两组患者的睡眠质量改善情况。血清学指标进行比较,并根据患者的病历回顾性计算两组间的不良反应发生率。
结果:在研究组和对照组中,有效率分别为95.00%和72.50%。治疗后,鼻塞的症状评分,鼻痒,打喷嚏,流鼻涕和匹兹堡睡眠质量指数(PSQI)总分明显低于研究组。治疗后,血清sVCAM-1,白细胞介素-4(IL-4),免疫球蛋白E(IgE)下降,IL-12水平上调。治疗后,在75Pa时,研究组的最小鼻横截面(NMCA)和总鼻阻力(TNR)降低更明显(p<0.05)。治疗后,外周血中CCL26和CCR3的表达水平显著降低。在对照组和研究组中,不良反应发生率分别为7.50%和10.00%。
结论:氮卓斯汀鼻喷雾剂联合贻贝黏蛋白治疗变应性鼻炎有效,能有效改善患者的临床症状,缓解鼻腔通气障碍,减少炎症反应,改善睡眠质量。这种联合治疗的策略是安全的,因此,值得提倡。
OBJECTIVE: A retrospective study was conducted to investigate the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis (AR) and the effects of CCL26 and CC chemokine receptor-3 (CCR3).
METHODS: A total of 80 patients with AR admitted to our hospital from March 2020 to March 2022 were included as the research objects. All subjects were divided into two groups according to the different therapeutic strategies by reviewing the patient\'s treatment. The control group (n = 40) was given azelastine nasal spray, while the study group (n = 40) was treated with a combination of mussel mucin and azelastine nasal spray. The clinical efficacy, clinical symptoms, and sleep quality improvement of the two groups were calculated and compared retrospectively. The serological indexes were compared, and the incidence of adverse reactions between the two groups was calculated retrospectively based on the patient\'s medical records.
RESULTS: In the study and control groups, the effective rate was 95.00% and 72.50%. After treatment, the symptom scores of nasal congestions, nasal itching, sneezing, and runny nose and the total score of Pittsburgh sleep quality index (PSQI) in the study group were remarkably less. After treatment, the serum levels of sVCAM-1, interleukin-4 (IL-4), and immunoglobulin E (IgE) were decreased, and the levels of IL-12 were upregulated. Following treatment, Minimum nasal cross-section (NMCA) and total nasal resistance (TNR) at 75Pa in the study group were reduced more noticeably (p < 0.05). After treatment, the expression levels of CCL26 and CCR3 in peripheral blood were significantly decreased. In the control and study groups, the incidence of adverse reactions was 7.50% and 10.00%.
CONCLUSIONS: Azelastine nasal spray combined with mussel mucin is effective in the treatment of allergic rhinitis, which can effectively improve patients\' clinical symptoms, alleviate nasal ventilation disorders, reduce inflammatory reactions, and improve sleep quality. This strategy of combined treatment is safe and, therefore, worth advocating.